Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07787182 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease

StatusNot Yet Recruiting
PhasePhase 1
Started2026-09
View on ClinicalTrials.gov ↗
The purpose of this study is to see how safe LY4405094 is and to see how much and how quickly LY4405094 gets into the bloodstream. For healthy participants, the study also looks at how much LY4405094 gets into the fluid around the brain and lasts up to 13 weeks and will include a 4-day stay in the Clinical Research Unit (CRU). For participants with Alzheimer's Disease, the study will also look at levels of a specific Alzheimer's-related protein in the brain and will last up to 25 weeks and will include a 3-day stay in the CRU.
Trial Details
NCT Number NCT07787182
Lead Sponsor Eli Lilly and Company
Conditions Healthy Volunteers, Alzheimer Disease, Amyloid, Plaque, Amyloid
Enrollment 68 participants
Start Date 2026-09
Primary Completion 2028-01 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-26